Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Supernus Pharmaceuticals (NASDAQ:SUPN) is set to report earnings Tuesday after market close. The prior quarter saw revenue of $207.7M, up 38.6% YoY, but EPS missed expectations. For the upcoming quarter, analysts expect revenue growth of 24.3% YoY. The article cites an average analyst price target of $63.50 versus a $45.01 share price.
How this was made
The 30-second read
Why it matters
Traders can use the provided consensus expectations (revenue +24.3% YoY) and the prior quarter’s mixed outcome to form scenarios for EPS and guidance versus Street expectations.
Market read
This is a pre-earnings checklist for SUPN with specific prior-quarter performance and upcoming-quarter revenue growth expectations, but no new company-specific disclosure beyond the earnings timing.
What to watch
The article does not specify what drove the prior EPS miss or whether guidance is for the full year versus quarter, which can materially change the earnings reaction.
Background
The article frames SUPN as reporting Tuesday after market hours, referencing last quarter’s revenue beat ($207.7M, +38.6% YoY) and EPS estimate miss.
Ticker impact
Supernus Pharmaceuticals (SUPN) reports earnings Tuesday after the close, with prior-quarter revenue $207.7M and EPS guidance miss.
Near-term volatility likely around results, with direction dependent on EPS versus expectations and any guidance changes.
The article provides concrete prior-quarter figures (revenue beat, EPS miss) and consensus expectations for the upcoming quarter, but no new guidance or datapoint beyond the earnings preview.
Market effects
Pharma earnings read-through is mixed in the article via Corcept and Bristol Myers, but SUPN-specific guidance is the main driver.
Primarily US small/mid-cap pharma sentiment into the earnings window.
Limited, as the piece is a single-company earnings preview with no global policy or supply-chain shock.
Counterpoint
If investors focus on the revenue growth re-acceleration (24.3% expected) and operating income guidance, the EPS miss may be discounted, supporting a rebound.
Key entities
- companySupernus Pharmaceuticals
NASDAQ-listed specialty pharma company scheduled to report earnings Tuesday after market hours.
- companyCorcept
Peer cited for Q2 results (revenue +7.3% YoY, missed by 1%) and a +27.3% post-results move.
- companyBristol-Myers Squibb
Peer cited for Q2 results (revenue +5.7% YoY, beat by 12.9%) and a +3% post-results move.
